<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687817</url>
  </required_header>
  <id_info>
    <org_study_id>PPHM 0701</org_study_id>
    <nct_id>NCT00687817</nct_id>
  </id_info>
  <brief_title>Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peregrine Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peregrine Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the overall response rate (complete
      response + partial response) to a combination of bavituximab plus carboplatin and paclitaxel
      in patients with previously untreated locally advanced or metastatic non-small cell lung
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response (complete response + partial response) to a combination of bavituximab plus carboplatin and paclitaxel in patients with previously untreated locally advanced or metastatic non-small-cell lung cancer</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression, duration of response, overall survival and safety</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">49</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bavituximab plus paclitaxel and carboplatin</intervention_name>
    <description>Weekly bavituximab dose of 3 mg/kg until disease progression, and up to 6 cycles of carboplatin at a dose of AUC=5 and paclitaxel 175 mg/m2 every 21 days (21-day cycles)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Adults over age 18 years of age with a life expectancy of at least 3 months

          -  Histologically or cytologically confirmed non-small cell lung cancer at stage IIIB
             (with pleural effusion), stage IV, or recurrence

          -  Measurable disease on cross sectional imaging at least 2 cm in longest diameter (1 cm
             if measured by spiral CT)

          -  Adequate hematologic (ANC ≥ 1500 cells/µL; Hemoglobin ≥9 g/dL; platelets ≥100,000/µL
             and ≤500,000/µL ), renal (serum creatinine ≤ 1.5 mg/dL or calculated creatinine
             clearance ≥ 60 mL/min), and hepatic function (bilirubin ≤ 1.5 x ULN, ALT ≤ 3 x ULN,
             AST ≤ 3 x ULN)

          -  D-dimer ≤ 2 x ULN

        Key Exclusion Criteria:

          -  Small cell or mixed histology

          -  Known history of bleeding diathesis or coagulopathy

          -  Any current evidence of clinically significant bleeding defined as gross hematuria,
             hemoptysis, or GI bleeding

          -  Any history of thromboembolic events (e.g., deep vein thrombosis or pulmonary
             thromboembolism)

          -  Prior chemotherapy, immunotherapy or radiotherapy to an area of measurable disease
             unless disease had recurred after radiotherapy

          -  Radiotherapy within 2 weeks preceding Study Day 1

          -  Symptomatic or clinically active CNS disease or metastatic lesions

          -  Major surgery within 4 weeks of Study Day 1

          -  Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease)

          -  Any history of angina pectoris, coronary artery disease or cerebrovascular accident,
             or transient ischemic attack

          -  A history of any condition requiring anti-platelet therapy with the exception of
             general cardiovascular prophylaxis with aspirin. Anti-platelet agents are prohibited
             during the study.

          -  Requirement for chronic daily treatment with NSAIDs, anti-platelet drugs, or steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Apollo Hospital</name>
      <address>
        <city>Bannerghatta Rd.</city>
        <state>Banglore</state>
        <zip>560 076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidwai Hospital</name>
      <address>
        <city>Munigowda Road</city>
        <state>Banglore</state>
        <zip>560 027</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M S Ramaiah Hospital</name>
      <address>
        <city>New BEL Rd</city>
        <state>Banglore</state>
        <zip>560 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bangalore Institute of Oncology Speciality Centre</name>
      <address>
        <city>Sampangi Ram Nagar</city>
        <state>Banglore</state>
        <zip>560 027</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizam's Institute of Medical Sciences</name>
      <address>
        <city>Panjagutta</city>
        <state>Hyderabad</state>
        <zip>500 082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yashoda Hospital</name>
      <address>
        <city>Somajiguda</city>
        <state>Hyderabad</state>
        <zip>500 082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCC Medical College</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <zip>695 011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orchid Nursing Home</name>
      <address>
        <city>Phoolanbhaghan</city>
        <state>Kolkata</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <zip>411-001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2008</study_first_posted>
  <last_update_submitted>March 23, 2011</last_update_submitted>
  <last_update_submitted_qc>March 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>A.J. Leyco, RN/Associate Director, Clinical Affairs</name_title>
    <organization>Peregrine Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

